Work

Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2058

Authors: Jian Li Campian, Omar H. Butt, Jiayi Huang, Jingqin Luo, Yu Tao, Roy E. Strowd, Deanna C Hissim, Sani Haider Kizilbash, Christopher Abraham, George Ansstas, Tanner Michael Johanns, Albert H. Kim, Matthew A. Ciorba, Milan G Chheda

Institutions: Mayo Clinic, Washington University in St. Louis, Wake Forest University Health Sciences, Wake Forest University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Incyte

OpenAlex ID: W4286296491

Cites:

Cited by: 6

Related to: 10